ATE416175T1 - 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen - Google Patents
2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungenInfo
- Publication number
- ATE416175T1 ATE416175T1 AT02712572T AT02712572T ATE416175T1 AT E416175 T1 ATE416175 T1 AT E416175T1 AT 02712572 T AT02712572 T AT 02712572T AT 02712572 T AT02712572 T AT 02712572T AT E416175 T1 ATE416175 T1 AT E416175T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- arylaminopyrimidines
- gsk3
- related diseases
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26990301P | 2001-02-20 | 2001-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE416175T1 true ATE416175T1 (de) | 2008-12-15 |
Family
ID=23029104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02712572T ATE416175T1 (de) | 2001-02-20 | 2002-02-18 | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
Country Status (17)
Country | Link |
---|---|
US (1) | US7078410B2 (de) |
EP (1) | EP1423388B1 (de) |
JP (1) | JP4309657B2 (de) |
KR (1) | KR20030076688A (de) |
CN (1) | CN100415744C (de) |
AT (1) | ATE416175T1 (de) |
BR (1) | BR0207096A (de) |
CA (1) | CA2435177A1 (de) |
DE (1) | DE60230160D1 (de) |
ES (1) | ES2316546T3 (de) |
HK (1) | HK1094697A1 (de) |
IL (1) | IL156784A0 (de) |
MX (1) | MXPA03007266A (de) |
NO (1) | NO20033677L (de) |
NZ (1) | NZ527009A (de) |
WO (1) | WO2002066480A2 (de) |
ZA (1) | ZA200306175B (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2004050091A1 (ja) * | 2002-12-03 | 2004-06-17 | Kyorin Pharmaceutical Co., Ltd. | ホスホジエステラーゼ10a阻害剤 |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
BRPI0516597A (pt) * | 2004-10-13 | 2008-09-16 | Wyeth Corp | composto da fórmula |
JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | スピロ2,4−ピリミジンジアミン化合物およびその使用 |
EP1828183A1 (de) * | 2004-12-17 | 2007-09-05 | AstraZeneca AB | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamide als cdk-inhibitoren |
US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
EP1856135B1 (de) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
AU2006251989B2 (en) * | 2005-05-20 | 2010-05-27 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
SG137989A1 (en) | 2005-06-08 | 2008-01-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK pathway |
UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
WO2007040436A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer’s disease |
GB0520958D0 (en) | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
JP2009531390A (ja) * | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
WO2008003766A2 (en) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
EP2102194A1 (de) * | 2006-12-08 | 2009-09-23 | F. Hoffmann-Roche AG | Substituierte pyrimidine und ihre verwendung als jnk-modulatoren |
CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
CA2715658C (en) | 2008-02-15 | 2016-07-19 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
WO2010002985A1 (en) | 2008-07-01 | 2010-01-07 | Ptc Therapeutics, Inc. | Bmi-1 protein expression modulators |
EP2303881A2 (de) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Kondensierte heterocyclische hemmer von histondeacetylase und/oder cyclin-abhängigen kinasen |
JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物 |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
NZ590747A (en) | 2008-07-28 | 2012-11-30 | Gilead Sciences Inc | Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds |
WO2010049731A1 (en) * | 2008-10-29 | 2010-05-06 | Astrazeneca Ab | Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors |
CN101735211B (zh) * | 2008-11-04 | 2012-11-14 | 复旦大学 | 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途 |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
RU2011140238A (ru) | 2009-04-15 | 2013-05-20 | Астразенека Аб | Имидазол-замещенные пиримидины, полезные в лечении заболеваний, ассоциированных с киназой-3 гликогенсинтазы, таких как болезнь альцгеймера |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
US8258316B2 (en) | 2009-06-08 | 2012-09-04 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline HDAC inhibitor compounds |
AU2010259042A1 (en) | 2009-06-08 | 2011-12-15 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도 |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
CN103619846B (zh) | 2011-06-27 | 2016-08-17 | 詹森药业有限公司 | 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物 |
CN102391264A (zh) * | 2011-09-21 | 2012-03-28 | 河北九派制药有限公司 | 6-溴咪唑并[1,2-a]吡啶的制备方法 |
EP2671885A1 (de) | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-Oxadiazol- und Imidazo-Thiadiazolderivate |
CN104411312B (zh) | 2012-06-26 | 2018-03-06 | 詹森药业有限公司 | 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合 |
ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
CA2886187C (en) * | 2012-09-28 | 2020-04-14 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
SG10201600149VA (en) | 2012-11-21 | 2016-02-26 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
CA2922657C (en) * | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN106362155A (zh) * | 2016-10-08 | 2017-02-01 | 无锡汉强医药科技有限公司 | Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用 |
JP2020502117A (ja) | 2016-12-16 | 2020-01-23 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺生物剤化合物 |
EP3765460A1 (de) | 2018-03-14 | 2021-01-20 | Vanderbilt University | Hemmung von bmp-signalisierung, verbindungen, zusammensetzungen und verwendungen davon |
KR102249521B1 (ko) | 2018-11-14 | 2021-05-07 | 아이알링크 주식회사 | 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG47583A1 (en) | 1986-01-13 | 1998-04-17 | American Cyanamid Co | 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines |
GB8901423D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
EP1317433A2 (de) * | 2000-09-06 | 2003-06-11 | Chiron Corporation | Inhibitoren von glycogen synthase kinase 3 |
-
2002
- 2002-02-18 BR BR0207096-0A patent/BR0207096A/pt not_active IP Right Cessation
- 2002-02-18 IL IL15678402A patent/IL156784A0/xx unknown
- 2002-02-18 JP JP2002565994A patent/JP4309657B2/ja not_active Expired - Fee Related
- 2002-02-18 US US10/468,605 patent/US7078410B2/en not_active Expired - Fee Related
- 2002-02-18 CA CA002435177A patent/CA2435177A1/en not_active Abandoned
- 2002-02-18 AT AT02712572T patent/ATE416175T1/de not_active IP Right Cessation
- 2002-02-18 CN CNB028052528A patent/CN100415744C/zh not_active Expired - Fee Related
- 2002-02-18 DE DE60230160T patent/DE60230160D1/de not_active Expired - Lifetime
- 2002-02-18 WO PCT/SE2002/000270 patent/WO2002066480A2/en active Application Filing
- 2002-02-18 NZ NZ527009A patent/NZ527009A/en unknown
- 2002-02-18 KR KR10-2003-7010875A patent/KR20030076688A/ko not_active Application Discontinuation
- 2002-02-18 ES ES02712572T patent/ES2316546T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP02712572A patent/EP1423388B1/de not_active Expired - Lifetime
- 2002-02-18 MX MXPA03007266A patent/MXPA03007266A/es active IP Right Grant
-
2003
- 2003-08-08 ZA ZA2003/06175A patent/ZA200306175B/en unknown
- 2003-08-19 NO NO20033677A patent/NO20033677L/no unknown
-
2007
- 2007-01-24 HK HK07100849.6A patent/HK1094697A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA03007266A (es) | 2003-12-04 |
JP2004522777A (ja) | 2004-07-29 |
NO20033677L (no) | 2003-10-02 |
WO2002066480A2 (en) | 2002-08-29 |
CN100415744C (zh) | 2008-09-03 |
CA2435177A1 (en) | 2002-08-29 |
NZ527009A (en) | 2006-04-28 |
ES2316546T3 (es) | 2009-04-16 |
CN1823064A (zh) | 2006-08-23 |
US20040106574A1 (en) | 2004-06-03 |
HK1094697A1 (en) | 2007-04-04 |
JP4309657B2 (ja) | 2009-08-05 |
EP1423388B1 (de) | 2008-12-03 |
WO2002066480A3 (en) | 2004-04-01 |
EP1423388A2 (de) | 2004-06-02 |
DE60230160D1 (de) | 2009-01-15 |
IL156784A0 (en) | 2004-02-08 |
BR0207096A (pt) | 2004-01-20 |
US7078410B2 (en) | 2006-07-18 |
NO20033677D0 (no) | 2003-08-19 |
KR20030076688A (ko) | 2003-09-26 |
ZA200306175B (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60230160D1 (de) | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen | |
ATE545660T1 (de) | Verfahren zur herstellung von niedermolekularem kationischem polygalactomannan mit verringertem geruch | |
BR0108734A (pt) | Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas | |
DE59603187D1 (de) | Verfahren zur herstellung von organisch modifizierten aerogelen, bei dem die gebildeten salze ausgefällt werden | |
RU2006116252A (ru) | Водные композиции, содержащие метронидазол | |
DE59607548D1 (de) | Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln | |
MXPA04000480A (es) | Proceso para la hidrolisis de proteinas lacteas. | |
WO2004049819A3 (en) | Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein | |
RU95101376A (ru) | Способ снижения содержания органического и неорганического галогена в водном растворе азотсодержащей смолы и применение водного раствора азотсодержащей смолы | |
DE60234032D1 (de) | Verfahren zur herstellung von chitosan | |
DE60043994D1 (de) | Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung | |
CA2015235A1 (en) | Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent | |
BRPI0416088A (pt) | composição, sistema, e método de tratar condições tais como calcificação vascular | |
TW200519080A (en) | Agent containinf (2R)-2-propyloctanic acid as effective component | |
DE60220193D1 (de) | Einwertiges salz verbessert die löslichkeit von milchproteinkonzentrat | |
WO2002067952A8 (en) | Prophylactic teat treatment | |
DE69811758T2 (de) | Verwendung von Hyaluronsäure zur Herstellung einer wässrigen Lösung verwendbar als intra-artikulare Reinigungslösung | |
FR2866890B1 (fr) | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant | |
BRPI0416427A (pt) | suspensão aquosa e método de preparação de suspensão aquosa | |
NO20033705L (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
SE0101307D0 (sv) | An effervescent solid composition of matter | |
DE60322738D1 (de) | Verfahren zur herstellung einer medizinischen lösung zur herstellung eines medikaments für die peritonealdialyse | |
ATE297665T1 (de) | Verfahren zur herstellung von tomatenflocken | |
NO20033707D0 (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
ATE235824T1 (de) | Verfahren zur herstellung von polyvinylpyrrolidon-iod in wässriger lösung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |